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New Clinical Relevance of Leukoaraiosis
To the Editor:
Changes in the cerebral white matter are detected with high
frequency by CT and MRI in aged individuals.1 The descriptive term
leukoaraiosis, meaning rarefaction of the white matter, was proposed
some 10 years ago to describe these radiological changes.2 Although
the mechanism of leukoaraiosis in different clinical conditions such as
Alzheimer’s disease or stroke remains undefined, vascular mechanisms
probably underlie a reasonably large part of these alterations.3 Leuko-
araiosis has been inconsistently associated with cognitive impairment,
assorted motor dysfunctions, and gait disturbances, but its contribution
to Alzheimer’s disease and vascular dementia is controversial.1 Part of
these discrepancies stem from different sensitivities of rating scales for
white matter changes, small sample sizes of patients, and use of
disparate neuropsychological tests.1
Recently, new evidence has suggested that leukoaraiosis may be
clinically important. First, patients with leukoaraiosis have a poor
prognosis in terms of death, stroke, and myocardial infarction. This has
been documented both in patients with motor impairment and
extensive leukoaraiosis on CT4 and in clinically heterogeneous pa-
tients with any degree of leukoaraiosis.5 Second, the results of
prospective studies indicate that leukoaraiosis may be an independent
and strong predictor of dementia in stroke patients.6,7 Among 300
patients with TIA, cerebral infarction, or intracerebral hemorrhage,
those with poststroke dementia showed leukoaraiosis on their entry
CT scan three times more frequently than nondemented patients.7
Third, and most recent, the presence of leukoaraiosis increases the risk
of intracranial bleeding in patients with cerebrovascular diseases
treated with anticoagulants.8 The SPIRIT (Stroke Prevention In
Reversible Ischemia Trial) was a multicenter randomized study
designed to examine the role of oral anticoagulants and antiplatelet
drugs as secondary prevention treatments in sinus rhythm patients with
minor cerebral ischemic events of supposed atherothrombotic origin.
Anticoagulation was set at a rather high international normalized ratio
(INR) level (3 to 4.5), in accordance with Dutch national guidelines.
The trial had to be stopped prematurely after the first interim analysis
because of the excess of bleeding in the group of anticoagulated
patients. Major bleedings were reported in 53 of the 651 patients
randomized to warfarin treatment. About one half of all the bleedings
were intracranial hemorrhage, which were fatal in 17 cases. Age $65
years, elevated INR levels, and presence of leukoaraiosis on CT scan
were predictors of hemorrhage.8 The association between white
matter abnormalities and cerebral hemorrhage is not new, but it had
previously been explained primarily by the common association with
arterial hypertension.9 Since the strongest predictor of leukoaraiosis is
advanced age, the SPIRIT results need to be viewed with some
caution in the light of the possible confounding effects of age and
hypertension. Nevertheless, these data have already had an impact on
the scientific community: a second forthcoming randomized trial, the
European Stroke Prevention in Reversible Ischemia Trial (ESPRIT),
which will evaluate the preventive efficacy of warfarin in patients with
noncardioembolic stroke, lists the presence of leukoaraiosis among its
exclusion criteria. This will certainly raise the problems of definition
and grading of these changes on CT and MRI.
Thus, although much about the pathogenesis and clinical signifi-
cance of leukoaraiosis remains to be elucidated, white matter changes
relate to the prognosis of patients and can no longer be considered a
secondary issue. Moreover, the above-mentioned results will require
clinicians to examine in greater detail the status of the brain before
deciding optimal preventive measures. It is therefore essential that
investigators collaborate in the task of harmonizing the classification of
white matter changes to better understand the clinical and pathological
correlates. An European multinational research group (The European
Task Force on Age-Related White Matter Changes) has been recently
founded with these aims.
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